Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease
Leng, L.K.; Pancharoen, C.; Bunupuradah, T.; Thisyakorn, U.; Trinavarat, P.; Sosothikul, D.; Ananworanich, J.
Journal of the Medical Association of Thailand 90(9): 1937-1942
2007
ISSN/ISBN: 0125-2208 PMID: 17957942 Document Number: 14589
This report documents a case of infiltrating cervical spinal mass, most likely a spinal tumor, in a girl with HIV infection that regressed following HAART and without treatment of the tumor or any anti-infectives.
Document emailed within 1 workday
Related Documents
Koyanagi, A.; Humphrey, J.H.; Ntozini, R.; Nathoo, K.; Moulton, L.H.; Iliff, P.; Mutasa, K.; Ruff, A.; Ward, B.; Chidawanyika, H.; Hargrove, J.; Mahomva, A.I.; Majo, F.; Malaba, L.C.; Mbizvo, M.T.; Mzengeza, F.; Ndhlovu, M.; Piwoz, E.; Propper, L.; Rambanepasi, P.; Ruff, A.J.; Tavengwa, N.; Zijenah, L.S.; Zunguza, C.D.; Zvandasara, P. 2011: Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy Pediatric Infectious Disease Journal 30(1): 45-51Breuckmann, F.; Neumann, T.; Kondratieva, J.; Wieneke, H.; Ross, B.; Nassenstein, K.; Barkhausen, J.; Kreuter, A.; Brockmeyer, N.; Erbel, R. 2005: Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART) European Journal of Medical Research 10(9): 395-399
Chandrasekhar, A.; Gupta, A. 2011: Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART? American Journal of Clinical Nutrition 94(6): 1703s-1715s
De Giorgio, F.; Abbate, A.; Capelli, A.; Arena, V. 2005: Spontaneous rupture of coronary artery in human immunodeficiency virus-positive patient treated with highly active anti-retroviral therapy (HAART) American Journal of Forensic Medicine and Pathology 26(2): 197
Guo, F.-p.; Yu, X.-b.; Luo, L.; Han, Y.; Qiu, Z.-f.; Zuo, L.-y.; Li, Y.-l.; Yu, W.; Li, T.-s. 2010: The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients Zhonghua Nei Ke Za Zhi 49(8): 649-652
Pomerantz, R.J. 1999: HIV patients receiving HAART therapy can still transmit the virus. Highly active antiretroviral chemotherapy American Family Physician 59(10): 2855
Venkatesh, K.K.; Biswas, J.; Kumarasamy, N. 2008: Impact of highly active antiretroviral therapy on ophthalmic manifestations in human immunodeficiency virus / acquired immune deficiency syndrome Indian Journal of Ophthalmology 56(5): 391-393
Chitra, P.; Bakthavatsalam, B.; Palvannan, T. 2011: Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy Clinica Chimica Acta; International Journal of Clinical Chemistry 412(11-12): 1151-1154
Palacios, G.C.; Montalvo, M.S.; Fraire, M.I.; Leon, E.; Alvarez, M.T.; Solorzano, F. 2008: Audiologic and vestibular findings in a sample of human immunodeficiency virus type-1-infected Mexican children under highly active antiretroviral therapy International Journal of Pediatric Otorhinolaryngology 72(11): 1671-1681
Sharma, M.; Legesse, H. 2016: Parametric Modeling of Survival Data Based on Human Immune Virus (HIV) Infected Adult Patients under Highly Active Antiretroviral Therapy (HAART): a Case of Zewditu Referral Hospital, Addis Ababa (AA), Ethiopia International Journal of Statistics in Medical Research 5(4): 240-247
Farquhar, C.; Wamalwa, D.; Selig, S.; John-Stewart, G.; Mabuka, J.; Majiwa, M.; Sutton, W.; Haigwood, N.; Wariua, G.; Lohman-Payne, B. 2009: Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination Pediatric Infectious Disease Journal 28(4): 295-299
Marazzi, M.C.; Nielsen-Saines, K.; Buonomo, E.; Scarcella, P.; Germano, P.; Majid, N.A.; Zimba, I.; Ceffa, S.; Palombi, L. 2009: Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding Pediatric Infectious Disease Journal 28(6): 483-487
Vibhagool, A.; Sungkanuparph, S.; Mootsikapun, P.; Chetchotisakd, P.; Tansuphaswaswadikul, S.; Bowonwatanuwong, C.; Ingsathit, A. 2003: Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 36(10): 1329-1331
Sulaiman, M.M.; Shettima, J.; Ummate, I.; Arogundade, F.A.; Yusuph, H.; Nwankwo, E.; Sanusi, A.A.; Akinsola, A. 2022: Comparative Evaluation of Prevalence, Risk Factors, and Pathologic Features of Kidney Disease in Highly Active Antiretroviral Therapy-Naive and Highly Active Antiretroviral Therapy-Experienced Patients at a Tertiary Health Facility in Maiduguri, Northeastern Nigeria Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation Saudi Arabia 33(1): 72-79
Iduoriyekemwen, N.J.; Sadoh, W.E.; Sadoh, A.E. 2013: Prevalence of renal disease in Nigerian children infected with the human immunodeficiency virus and on highly active anti-retroviral therapy Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation Saudi Arabia 24(1): 172-177
Ramana, K.V.; Sabitha, V.; Rao, R. 2013: A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era Journal of Clinical and Diagnostic Research: Jcdr 7(7): 1332-1335
Edlin, B.R. 1999: Change of HAART. Highly active antiretroviral therapy Lancet 353(9167): 1888
Podzamczer, D.; Barros, C.; Berenguer, J.; Gutiérrez, Félix.; Iribarren, Jé.Antonio.; Miró, Jé.M.; Molina, Jé.Pérez.; Podzamczer, D.; Aguirrebengoa, K.; Arribas, Jé.Ramón.; Boix, V.; Cahn, P.; Castro, A.; Caylá, J.; Cobo, J.; Corzo, J.Enrique.; de la Torre, J.; Dronda, F.; Ena, J.; Falcó, Vç.; Ferrer, E.; Labarga, P.; Locutura, J.; Mallolas, J.; Moreno, S.; Ocampo, A.; Ocaña, Ján.; Padilla, Bén.; Elías, Jús.Pérez.; Polo, R.; Portilla, Jín.; Riera, M.; Rivero, A.; Salavert, M.; Sanz, Jé. 2008: Treatment of opportunistic infections in adolescent and adult patients infected with the human immunodeficiency virus during the era of highly active antiretroviral therapy. AIDS Study Group (GESIDA) and National AIDS Plan Expert Committee Enfermedades Infecciosas y Microbiologia Clinica 26(6): 356-379
Nelwan, E.J. 2014: Adherence to highly active antiretroviral therapy (HAART) in HIV/AIDS patient Acta Medica Indonesiana 46(4): 273-274
Jallow, S.; Alabi, A.; Sarge-Njie, R.; Peterson, K.; Whittle, H.; Corrah, T.; Jaye, A.; Cotten, M.; Vanham, G.; McConkey, S.J.; Rowland-Jones, S.; Janssens, W. 2009: Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants Journal of Clinical Microbiology 47(7): 2200-2208